The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer

被引：0
|
作者：
Xia, Yang [1 ]
Huang, Xiu [1 ]
Jin, Rui [1 ]
Li, Wen [1 ]
Shen, Huahao [1 ]
机构：
[1] Zhejiang Univ, Hangzhou, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
D O I：
10.1183/13993003.congress-2019.PA4669
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4669
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer
    Harada, D.
    Kozuki, T.
    Nogami, N.
    Hotta, K.
    Aoe, K.
    Ohashi, K.
    Ninomiya, K.
    Hirata, T.
    Hinotsu, S.
    Toyooka, S.
    Kiura, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1829 - S1829
  • [22] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [23] Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine
    Hopkins, Ashley M.
    Rowland, Andrew
    Logan, Jessica M.
    Sorich, Michael J.
    BREAST, 2019, 46 : 90 - 94
  • [24] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Hirsch, FR
    Langer, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82
  • [25] Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.
    Li, Bob T.
    Shen, Ronglai
    Buonocore, Darren
    Olah, Zachary T.
    Ni, Ai
    Ginsberg, Michelle S.
    Ulaner, Gary
    Weber, Wolfgang
    Ladanyi, Marc
    Won, Helen H.
    Riely, Gregory J.
    Solit, David B.
    Hyman, David Michael
    Rudin, Charles M.
    Berger, Michael F.
    Scaltriti, Maurizio
    Baselga, Jose
    Kris, Mark G.
    Arcila, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
    Peters, Solange
    Stahel, Rolf
    Bubendorf, Lukas
    Bonomi, Philip
    Villegas, Augusto
    Kowalski, Dariusz M.
    Baik, Christina S.
    Isla, Dolores
    De Castro Carpeno, Javier
    Garrido, Pilar
    Rittmeyer, Achim
    Tiseo, Marcello
    Meyenberg, Christoph
    de Haas, Sanne
    Lam, Lisa H.
    Lu, Michael W.
    Stinchcombe, Thomas E.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 64 - 72
  • [27] Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
    Li, B.
    Offin, M.
    Hembrough, T.
    Cecchi, F.
    Shen, R.
    Olah, Z.
    Panora, E.
    Myers, M.
    Brzostowski, E.
    Buonocore, D.
    Ginsberg, M.
    Rudin, C.
    Kris, M.
    Weitsman, G.
    Barber, P.
    Ng, T.
    Ulaner, G.
    Arcila, M.
    Scaltriti, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S599 - S599
  • [28] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Spring, Laura M.
    Clark, Shealagh L.
    Li, Tianyu
    Goel, Shom
    Tayob, Nabihah
    Viscosi, Elene
    Abraham, Elizabeth
    Juric, Dejan
    Isakoff, Steven J.
    Mayer, Erica
    Moy, Beverly
    Supko, Jeffrey G.
    Tolaney, Sara M.
    Bardia, Aditya
    NPJ BREAST CANCER, 2021, 7 (01)
  • [29] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Laura M. Spring
    Shealagh L. Clark
    Tianyu Li
    Shom Goel
    Nabihah Tayob
    Elene Viscosi
    Elizabeth Abraham
    Dejan Juric
    Steven J. Isakoff
    Erica Mayer
    Beverly Moy
    Jeffrey G. Supko
    Sara M. Tolaney
    Aditya Bardia
    npj Breast Cancer, 7
  • [30] HER-2/NEU and ERCC1 in advanced non-small cell lung cancer
    Yoo, J.
    HISTOPATHOLOGY, 2010, 57 : 220 - 220
12345